EUVIMEDEUVIMED entdecken
Crossref

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance Mechanisms

Ali Majeed Ali Almukram, Hany Akeel Al-hussaniy, Mohammed A. Jabarah, Salah Hassan Zain Al-Abdeen

Medical and Pharmaceutical Journal · 2025 · 47-63

DOI: 10.55940/medphar202567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical and Pharmaceutical Journal, 2025. Verfasst von Ali Majeed Ali Almukram und 3 weiteren Autor:innen. Die Arbeit wurde bisher 17-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Worldwide, cancer is the primary cause of mortality. Research indicates that around half of all cancer types are caused by p53 mutations or downregulation. Alternative or complementary therapy methods are, therefore, desperately needed. The relationship between p53 and the proto-oncoprotein MDM2, a ubiquitin ligase frequently overexpressed in AML that causes the degradation of p53, is an intriguing place to start. Objective: this review aimed to summarize all research on MDM2 inhibitors and clinical studies, and recorded side effects and resistance profile.

Methods

Review articles compiled from over 100 publications in PubMed, Scopus, and ClinicalTrials.gov using keywords like MDM2 inhibitors.

Results

MDM2 antagonists efficiently stabilize p53, resulting in tumor suppression in malignancies of p53 wild-type individuals. Promising results have been seen in several Phase I and II clinical studies, especially in solid tumors and hematologic malignancies. Adverse effects and medication resistance are still problems, though. P53-targeting medications, on the other hand, may be able to restore P53 function in mutant forms, offering a new treatment option for tumors that have failed previous therapies.

Conclusion

P53 medications and MDM2 antagonists mark a substantial breakthrough in targeted cancer therapy. Although the initial clinical outcomes are promising, further investigation is needed to optimize their application, overcome resistance mechanisms, and integrate them into personalized treatment plans. Future developments in understanding P53-MDM2 interactions are likely to lead to more effective cancer treatments.

Zitieren

APA

Almukram, A. M. A., Al-hussaniy, H. A., Jabarah, M. A., & Al-Abdeen, S. H. Z. (2025). MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance Mechanisms. Medical and Pharmaceutical Journal, 47-63. https://doi.org/10.55940/medphar202567

Vancouver

Almukram AMA, Al-hussaniy HA, Jabarah MA, Al-Abdeen SHZ. MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance Mechanisms. Medical and Pharmaceutical Journal. 2025:47-63. doi:10.55940/medphar202567

BibTeX
@article{Almukram2025,
  author = {Almukram, Ali Majeed Ali and Al-hussaniy, Hany Akeel and Jabarah, Mohammed A. and Al-Abdeen, Salah Hassan Zain},
  title = {MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance Mechanisms},
  journal = {Medical and Pharmaceutical Journal},
  year = {2025},
  pages = {47--63},
  doi = {10.55940/medphar202567}
}
Kostenlos starten →